INFLECTIS BIOSCIENCE
InFlectis BioScience is leveraging its leading expertise in the cellular defense system against misfolded proteins and drug discovery to identify and develop small molecules which modulate key proteins involved in misfolded protein disorders. Endoplasmic Reticulum (ER) proteostasis is vital for cellular function and cell survival. Many different perturbations can alter the folding capacity of the ER and may cause accumulation of unfolded or misfolded proteins inside the ER, a cellular condition referred to as ER stress. To safeguard proteostasis, the mammalian ER has a complex machinery to maintain the integrity of cells. This adaptive programme is called the unfolded protein response (UPR).
INFLECTIS BIOSCIENCE
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2013-01-01
Address:
Nantes, Pays De La Loire, France
Country:
France
Website Url:
http://www.inflectis-bioscience.com
Total Employee:
1+
Status:
Closed
Contact:
+330251252000
Email Addresses:
[email protected]
Total Funding:
7.75 M EUR
Current Employees Featured
Founder
Investors List
Participations Besancon
Participations Besancon investment in Series A - InFlectis BioScience
Crédit Mutuel Innovation
Crédit Mutuel Innovation investment in Series A - InFlectis BioScience
GO CAPITAL
GO CAPITAL investment in Series A - InFlectis BioScience
Remiges Ventures
Remiges Ventures investment in Series A - InFlectis BioScience
GO CAPITAL
GO CAPITAL investment in Seed Round - InFlectis BioScience
Official Site Inspections
http://www.inflectis-bioscience.com
Unable to get host informations!!!
More informations about "InFlectis BioScience"
InFlectis BioScience | developing innovative therapeutics for …
Develop multifunctional, brain penetrant, small molecules that act on different major pathophysiological mechanisms implicated in neurological diseases. Potential new therapies …See details»
Board of Directors | InFlectis BioScience
Mark joined the Board of Directors of InFlectis BioScience in October 2021 as Chairman of the Board. Dr Pierre Miniouhas over 20 years of international experience in business development and licensing in the biopharmaceutical …See details»
InFlectis BioScience - LinkedIn
InFlectis BioScience is a private clinical-stage company aiming to target and modulate interactions between proteins involved in key human pathophysiological processes.See details»
InFlectis BioScience 2025 Company Profile: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for InFlectis BioScience. Use the PitchBook Platform to explore the full profile.See details»
Management - InFlectis BioScience
He began his career with the Dana group, a Fortune 250 company, in car component manufacturing and financial services. After developing the division’s financial strategy and …See details»
Reportable
Feb 11, 2025 He then left the laboratory activities to join the law firm Cabinet Regimbeau (Paris) prior to join Pierre Fabre Laboratories and in 2003 he moves to Vivalis (today Valneva) as Director of Business Development and Director …See details»
INFLECTIS BIOSCIENCE (NANTES) Chiffre d'affaires ... - Societe.com
Aug 30, 2013 INFLECTIS BIOSCIENCE, société par actions simplifiée, immatriculée sous le SIREN 795009604, est active depuis 11 ans. Située à NANTES (44200), elle est spécialisée …See details»
InFlectis BioScience Company Profile - Office Locations ... - Craft
InFlectis BioScience has 5 employees at their 1 location and $6.69 m in total funding,. See insights on InFlectis BioScience including office locations, competitors, revenue, financials, …See details»
Organization | InFlectis BioScience
InFlectis BioScience Report issue For profit Phase 2 Founded: Nantes France (2013) Status: Left NME R&D (2023) Organization Overview First Clinical Trial 2018 NCT03610334 First …See details»
InFlectis BioScience - Funding, Financials, Valuation & Investors
InFlectis BioScience is a private drug discovery company aiming at targeting.See details»
Inflectis - InFlectis BioScience Expands Leadership Team with Three ...
Oct 4, 2021 InFlectis BioScience Expands Leadership Team with Three Experienced International Appointments: Mark Pykett is Appointed Chairman, Béatrice Lejeune is …See details»
Inflectis Bioscience SAS - Drug pipelines, Patents, Clinical ... - Patsnap
Explore Inflectis Bioscience SAS with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 7 news, Disease Domain:Nervous System Diseases, Endocrinology and …See details»
InFlectis BioScience - Contacts, Employees, Board Members, …
InFlectis BioScience is a private drug discovery company aiming at targeting.See details»
IFB-088 slows disease progression in bulbar-onset ALS trial
Feb 11, 2025 “We are very encouraged by the results we observed with IFB-088,” Pierre Miniou, CEO of IFB-088’s developer Inflectis Bioscience, said in a company press release. “These …See details»
Our Pipeline - InFlectis BioScience
InFlectis is developing a class of small molecules for the treatment of neuromuscular diseases. These are orally-available compounds intended to prolong the Integrated Stress Response …See details»
News-20250206 - Remiges Ventures
Feb 6, 2025 InFlectis BioScience is now seeking global partners to complete the development and registration of IFB-088 in ALS and leverage the company’s assets in a broader pipeline of …See details»
Our Commitment - InFlectis BioScience
We’re a biotechnology company developing new treatments for people living with neurological diseases like Amyotrophic Lateral Sclerosis (ALS), Charcot-Marie-Tooth (CMT) and Multiple …See details»
Inflectis - InFlectis BioScience Doses First Patient with IFB-088 in a ...
InFlectis BioScience is a France-based clinical stage company developing first-in-class therapies for neuromuscular diseases. InFlectis BioSciences' therapies are designed to boost a cellular …See details»
Inflectis - InFlectis BioScience Completes Enrollment of its Phase 2 ...
Jan 31, 2024 InFlectis completed enrollment in its Phase 2 clinical trial of IFB-088 in ALS. IFB-088 is capable of crossing the blood-brain barrier and believed to act by selectively inhibiting a …See details»